Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic...

"Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU."


+

021421 Exelixis Highlights Positive Resu
.
Download • 216KB